دورية أكاديمية
أعرض في EDS

The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients.

التفاصيل البيبلوغرافية
العنوان: The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients.
المؤلفون: Nakai Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan., Isayama H, Sasaki T, Takahara N, Saito K, Ishigaki K, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K
المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2015 May; Vol. 141 (5), pp. 933-9. Date of Electronic Publication: 2014 Nov 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer-Verlag.
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Pancreatic Neoplasms/*drug therapy , Pancreatic Neoplasms/*metabolism , Renin-Angiotensin System/*drug effects, Adult ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Odds Ratio ; Pancreatic Neoplasms/diagnostic imaging ; Pancreatic Neoplasms/pathology ; Proportional Hazards Models ; Retrospective Studies ; Tomography, X-Ray Computed ; Treatment Outcome ; Gemcitabine
مستخلص: Purpose: The role of local renin-angiotensin system (RAS) as a target for the treatment of pancreatic cancer has been increasingly reported, but the addition of candesartan, one of angiotensin system inhibitors (ASIs), to gemcitabine in our prospective trial failed to demonstrate activity against pancreatic cancer. The aim of this study was to explore subgroups that would benefit from the inhibition of RAS by the use of ASIs.
Methods: Consecutive patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy were retrospectively studied. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were estimated by a Cox proportional hazards model. Interactions between the use of ASIs and each subgroup were tested.
Results: Between 2001 and 2013, 349 patients received gemcitabine-based chemotherapy for advanced pancreatic cancer; 232 were metastatic, 210 received gemcitabine monotherapy, 108 took ASIs, 166 were never smokers and 188 were diabetic. The median PFS and OS were 4.9 and 11.2 months, respectively. When the effects of the use of ASIs were evaluated by a Cox proportional hazard model, there were two subgroups with P interaction <0.10 both in PFS and OS: never smokers and gemcitabine monotherapy. HRs for PFS and OS by the inhibition of RAS were 0.71 (P = 0.021) and 0.68 (P = 0.014) in never smokers and 0.70 (P = 0.027) and 0.77 (P = 0.124) in patients receiving gemcitabine monotherapy.
Conclusion: The inhibition of RAS in advanced pancreatic cancer might improve clinical outcomes in cases without a history of smoking or in cases receiving gemcitabine monotherapy.
References: Clin Gastroenterol Hepatol. 2009 Sep;7(9):1007-12. (PMID: 19560558)
Br J Cancer. 2010 Nov 23;103(11):1644-8. (PMID: 20978506)
Gastroenterology. 2003 Apr;124(4):1010-9. (PMID: 12671898)
Invest New Drugs. 2013 Oct;31(5):1294-9. (PMID: 23690239)
Am J Gastroenterol. 2011 Jun;106(6):1161-6; quiz 1167. (PMID: 21577244)
Carcinogenesis. 2008 Sep;29(9):1675-84. (PMID: 18632755)
Ann Oncol. 2009 Aug;20(8):1397-401. (PMID: 19457938)
Cancer. 2006 Jun 1;106(11):2428-36. (PMID: 16634096)
Ann Oncol. 2012 Jul;23(7):1880-8. (PMID: 22104574)
Oncologist. 2014 Jan;19(1):51-60. (PMID: 24309979)
N Engl J Med. 2011 May 12;364(19):1817-25. (PMID: 21561347)
Pancreas. 2011 Aug;40(6):931-7. (PMID: 21747317)
N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140)
Clin Gastroenterol Hepatol. 2011 Mar;9(3):266-73; quiz e27. (PMID: 21029787)
Cancer Sci. 2012 Aug;103(8):1489-92. (PMID: 22515232)
Br J Cancer. 2012 Jun 5;106(12):1934-9. (PMID: 22555398)
Genes Dev. 2006 Nov 15;20(22):3147-60. (PMID: 17114585)
J Cancer Res Clin Oncol. 2009 Oct;135(10):1429-35. (PMID: 19399518)
Arch Intern Med. 2009 Jun 8;169(11):1035-45. (PMID: 19506173)
Expert Opin Biol Ther. 2009 Aug;9(8):945-9. (PMID: 19534585)
Oncology. 2009;77(5):300-3. (PMID: 19923869)
Ann Surg Oncol. 2012 Nov;19(12):3987-93. (PMID: 22872290)
Pancreas. 2004 Jan;28(1):38-44. (PMID: 14707728)
Eur J Cancer. 2014 Jan;50(1):193-203. (PMID: 24054979)
Oncology. 2010;78(3-4):249-58. (PMID: 20523085)
J Gastroenterol. 2008;43(11):823-32. (PMID: 19012035)
Scand J Gastroenterol. 2013 May;48(5):602-9. (PMID: 23477656)
Cancer Res. 2008 Nov 15;68(22):9112-5. (PMID: 19010879)
Cancer Res. 2009 Apr 15;69(8):3681-8. (PMID: 19351817)
Cancer Sci. 2011 Feb;102(2):425-31. (PMID: 21175992)
Pancreas. 2014 Oct;43(7):1014-7. (PMID: 24979618)
Oncology. 2013;85(4):216-22. (PMID: 24080957)
Pancreas. 2014 Jan;43(1):47-52. (PMID: 24177141)
Science. 2009 Jun 12;324(5933):1400-1. (PMID: 19520948)
J Clin Oncol. 2007 May 20;25(15):1960-6. (PMID: 17452677)
J Clin Oncol. 1997 Jun;15(6):2403-13. (PMID: 9196156)
Oncology. 2012;83(6):354-60. (PMID: 23052034)
Int J Cancer. 2010 Nov 15;127(10):2412-9. (PMID: 20143395)
Am J Gastroenterol. 2012 Nov;107(11):1730-9. (PMID: 22929760)
Cancer Chemother Pharmacol. 2014 Nov;74(5):911-5. (PMID: 25143299)
المشرفين على المادة: 0 (Antimetabolites, Antineoplastic)
0W860991D6 (Deoxycytidine)
0 (Gemcitabine)
تواريخ الأحداث: Date Created: 20141116 Date Completed: 20150622 Latest Revision: 20221207
رمز التحديث: 20231215
DOI: 10.1007/s00432-014-1873-2
PMID: 25398651
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1335
DOI:10.1007/s00432-014-1873-2